A new scientific review from the European Journal of Clinical Pharmacology examined the potential therapeutic effects of cannabis-based medicine on Tourette syndrome and found that medical marijuana shows “promising and potentially effective outcomes…in mitigating the severity of tics and premonitory urges.”
While authors noted that further research—involving larger samples, fixed doses and “unified drug components”—are needed to accurately estimate their effectiveness, they said the studies indicated that cannabis-based medicine (CBM) could be a promising therapy for people with TS. “The present study suggests favorable and potentially effective results with CBM in reducing the severity of tics and premonitory urges,” they wrote, adding that the findings may be especially useful in light of the fact that patients with TS have few available treatment options.
Authors said they believe the research represents “the first systematic review and meta-analysis evaluating the effectiveness of CBM among patients with TS using various scales.”
